🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

140 results for “car-t” Clear

  1. CAR-T Cells

    The First People's Hospital of Lianyungang

    Lung Neoplasm Malignant

    phase 2 mab active

    1 trial

  2. CAR-T treatment

    The First People's Hospital of Lianyungang

    Multiple Myeloma

    phase 2 mab active

    1 trial

  3. CD123 CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Leukemia

    phase 2 mab active

    2 trials

  4. CD19 CAR T-Cell(CAT19T2)

    Zhujiang Hospital

    B-cell Acute Lymphoblastic Leukemia

    phase 2 mab terminated

    1 trial

  5. CD19 CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Autoimmune Diseases

    phase 2 mab active

    1 trial

  6. CD19 CAR-T cells

    The First People's Hospital of Lianyungang

    Acute Lymphoblastic Leukemia

    phase 2 mab active

    1 trial

  7. CD19 CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Leukemia

    phase 2 mab active

    2 trials

  8. CD19 CAR-T cells and CD19 positive feeder T cells

    The First People's Hospital of Lianyungang

    Acute Lymphoblastic Leukemia in Remission

    phase 2 mab active

    1 trial

  9. CD19 and CD22 targeted CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Leukemia, B-cell

    phase 2 mab active

    2 trials

  10. CD19 and CD22 targeted prime CAR- T cells

    Chongqing Precision Biotech Co., Ltd

    B Cell Lymphoma

    phase 2 mab active

    1 trial

  11. CD19 and CD22 targeted prime CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    B-ALL

    phase 2 mab active

    1 trial

  12. CD19 or CD20 CAR T cells briging HSCT

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lymphoma, Large B-Cell, Diffuse

    phase 2 mab active

    1 trial

  13. CD19X CAR-T

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Large B-Cell Lymphoma (LBCL)

    phase 2 small molecule active

    1 trial

  14. CD22/CD19 CAR T and auto-HSCT "sandwich" strategy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    B-cell Acute Lymphoblastic Leukemia

    phase 2 other active

    1 trial

  15. CEA CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Solid Tumor

    phase 2 mab active

    1 trial

  16. CEA-targeted CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Gastric Cancer

    phase 2 mab active

    3 trials

  17. Humanized CD7 CAR-T cells

    The First People's Hospital of Lianyungang

    T Lymphoblastic Leukemia/Lymphoma

    phase 2 mab active

    1 trial

  18. IL-15-armored CAR-T cells

    The First People's Hospital of Lianyungang

    Relapsed/Refractory Multiple Myeloma

    phase 2 mab active

    1 trial

  19. Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T cells

    The First People's Hospital of Lianyungang

    B Cell Lymphoma

    phase 2 mab active

    1 trial

  20. KYV-101 anti-CD19 CAR-T cell therapy

    Kyverna Therapeutics

    Lupus Nephritis

    phase 2 mab active

    2 trials

  21. LCAR-B38M CAR-T Cell

    Nanjing Legend Biotech Co.

    Multiple Myeloma

    phase 2 mab terminated

    1 trial

  22. LCAR-B38M CAR-T cell injection

    Nanjing Legend Biotech Co.

    Refractory or Relapsed Multiple Myeloma

    phase 2 mab active

    1 trial

  23. NXC-201 CAR-T

    Immix Biopharma

    Light Chain (AL) Amyloidosis

    phase 2 mab active

    1 trial

  24. PCAR-019 (anti-CD19 CAR-T cells)

    The First People's Hospital of Lianyungang

    Acute Lymphocytic Leukemia

    phase 2 mab active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources